In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor–Mediated Signaling in Ticagrelor-Treated Patients-Reference-Cited by-同舟云学术

In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor–Mediated Signaling in Ticagrelor-Treated Patients

Published:2017-07 Issue:13 Volume:10 Page:1374-1375
ISSN:1936-8798
Container-title:JACC: Cardiovascular Interventions
language:en
Short-container-title:JACC: Cardiovascular Interventions

Author:

Rollini Fabiana,Franchi Francesco,Thano Estela,Faz Gabriel,Park Yongwhi,Kureti Megha,Cho Jung Rae,Been Latonya,Bass Theodore A.,Angiolillo Dominick J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference5 articles.

1. Antithrombotic therapy for patients with STEMI undergoing primary PCI;Franchi;Nat Rev Cardiol,2017

2. Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study;Tello-Montoliu;J Am Coll Cardiol,2012

3. Pharmacodynamic effects of ticagrelor dosing regimens in patients on maintenance ticagrelor therapy: results from a prospective, randomized, double-blind investigation;Cho;J Am Coll Cardiol Intv,2015

4. Switching P2Y12-receptor inhibitors in patients with coronary artery disease;Rollini;Nat Rev Cardiol,2016

5. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients;Rollini;J Am Coll Cardiol Intv,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor;JACC: Cardiovascular Interventions;2023-01

2. Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention;Expert Review of Cardiovascular Therapy;2021-05-11

3. Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor;Journal of Thrombosis and Thrombolysis;2021-02-13

4. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor;Thrombosis and Haemostasis;2021-01-07

5. Pharmacodynamics During Transition Between Platelet P2Y12 Inhibiting Therapies;Interventional Cardiology Clinics;2019-10